|Name of Journal||Artificial Intelligence in Cancer|
|Title Abbreviation||Artif Intell Cancer|
|ISSN||There is currently no ISSN|
Intelligence in Cancer (AIC, Artif Intell Cancer) is a high-quality, online, open-access,
single-blind peer-reviewed journal that is published by the Baishideng
Publishing Group. Accepting both solicited and unsolicited manuscripts, the AIC mainly publishes high quality
clinical research articles to promote the application of artificial
intelligence in bone oncology,
breast cancer, gastrointestinal cancer, genitourinary cancer, gynecological cancer, head and neck cancer, hematologic malignancy,
lung cancer, lymphoma and myeloma, pediatric oncology, and urologic oncology research with the
ultimate objective of improving early screening, diagnosis, and treatment of these
diseases. The types of articles published in the AIC include Editorial, Opinion Review, Frontier, Review, Minireview,
Topic Highlight, Clinical Research, Systematic Review, Meta-analysis,
Evidence-based Medicine, Advances in Diagnosis, Advances in Treatment, Field of
Vision, Clinical Guidelines, Letter to the Editor, and Case Report.
The primary aim of the AIC is to provide scholars and readers from various fields of cancer research with a platform to publish high quality clinical research articles and communicate their research findings online. In order to ensure the quality, timeliness, fairness, and transparency of manuscript publication, the AIC has implemented a variety of measures.
First, authors must prepare their articles according to the appropriate international publication recommendations, including the STROBE Statement, CONSORT 2010 Statement, PRISMA 2009 Checklist, and CARE Checklist – 2016: Information for writing a case report.
Second, articles published in the AIC must undergo rigorous cross-international peer review, where peer reviewers and authors come from different countries and independent peer reviewers are chosen by the editorial office, not by authors, to ensure the fairness of peer review.
Third, designation of co-first authors or co-corresponding authors is not permitted.
Fourth, the AIC accepts a manuscript based mainly on its novelty, innovativeness, data accuracy, picture reliability, clear language expression, and ethical requirements. Of note, peer reviewers will complete the peer review within 7 days, providing a comprehensive evaluation of the scientific and linguistic quality of the manuscript.
Fifth, BPG adopts a 7-day publishing management policy. This means that each step of the publishing process, including manuscript preview, peer review, manuscript revision by authors, final acceptance, language editing, and production and release, must be completed within 7 days.
Finally, the peer review report, author’s response to the peer review report, biostatistics review certificate, copyright license agreement, institutional ethics committee approval document, informed consent, conflict-of-interest statement, CrossCheck detection report, authors’ personal ORCID numbers, funding information, language editing certificate, and other relevant documents will be published online along with the article to ensure that the publishing process is open and transparent.
The AIC mainly publishes clinical cancer research results obtained using artificial intelligence technology, including those from the clinical research of cancers as well as their genetic testing, histopathological diagnosis, cytological diagnosis, imaging diagnosis, ultrasonic diagnosis, epidemiology, clinical diagnosis, individualized treatment, radiotherapy, chemotherapy, and biological treatment.
|Open Access||Open access|
There is currently no indexing.
There is currently no impact factor.
|Article Processing Charge||Article processing charge|
|Article Reprints||Article reprints|
|Help Desk||Help desk|
|Special Statement||Special statement|
|Copyright ©||© 2004-2019 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA|
|Contact Us||Contact us|